GlassScriptPhysician profile
Barbara Sue Mcgrath
NPI 1780649327
$4,167.65
in general payments reported to CMS, 2019-2025
39 companies · $568 in 2025
The $568 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $80.17 · 2021: $447 · 2022: $628 · 2023: $1,173 · 2024: $700 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,229 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,229.13 |
| Education | $211.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $426.08 | 2019-2025 | Imfinzi, Breztri, Lynparza |
| Novartis Pharmaceuticals Corporation | $310.25 | 2021-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $306.66 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $281.71 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $270.24 | 2021-2024 | Reblozyl |
| Lilly USA, LLC | $197.36 | 2019-2023 | Verzenio, Jaypirca, Retevmo |
| Amgen INC. | $189.65 | 2019-2024 | Evenity, Prolia, Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $169.34 | 2021-2025 | Opdivo |
| Glaxosmithkline, LLC. | $159.42 | 2021-2024 | Zejula, Jemperli, Ojjaara |
| Tempus Ai, INC | $152.81 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.10 | 2019-2025 | Jardiance |
| Clovis Oncology, INC. | $122.92 | 2019-2020 | |
| Daiichi Sankyo INC. | $120.28 | 2022-2023 | Enhertu, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $107.90 | 2023 | Fruzaqla |
| Seagen INC. | $104.29 | 2023 | Padcev |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $99.95 | 2022 | |
| Eisai INC. | $99.00 | 2021 | |
| Abbvie INC. | $96.63 | 2019-2023 | |
| Incyte Corporation | $77.95 | 2025 | Jakafi |
| Genzyme Corporation | $70.29 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $61.28 | 2021-2024 | Ultomiris |
| Janssen Biotech, INC. | $57.94 | 2023 | Erleada |
| Gilead Sciences, INC. | $54.12 | 2022-2024 | Trodelvy |
| Genentech USA, INC. | $53.04 | 2021-2024 | Venclexta |
| Stemline Therapeutics INC. | $50.24 | 2023 | Orserdu |
| Pharmaessentia USA Corporation | $46.17 | 2022-2023 | Besremi |
| Astellas Pharma US INC | $44.47 | 2022-2023 | Xtandi |
| Dendreon Pharmaceuticals LLC | $35.18 | 2019 | |
| Rigel Pharmaceuticals, INC. | $32.07 | 2023-2024 | Tavalisse, Rezlidhia |
| Kite Pharma, INC. | $30.38 | 2023 | Yescarta |
| Sobi, INC | $27.80 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $26.16 | 2024 | Adstiladrin |
| Pfizer INC. | $25.25 | 2019-2023 | |
| Karyopharm Therapeutics INC. | $23.13 | 2023 | Xpovio |
| Foundation Medicine, INC. | $22.88 | 2023 | Foundationone Cdx |
| G1 Therapeutics, INC. | $17.00 | 2023 | Cosela |
| Progenics Pharmaceuticals, INC. | $15.66 | 2023 | Pylarify |
| Puma Biotechnology, INC. | $15.63 | 2023 | |
| Tersera Therapeutics LLC | $14.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Mcgrath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.